Tuesday, November 15, 2016 7:49:02 AM
https://baseballnewssource.com/markets/atossa-genetics-inc-atos-releases-earnings-results-beats-estimates-by-1-35-eps/225669.html
Recent ATOS News
- Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates (ADCs) and (Z)-Endoxifen • GlobeNewswire Inc. • 04/29/2024 12:30:00 PM
- Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer • GlobeNewswire Inc. • 04/15/2024 12:30:00 PM
- Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference • GlobeNewswire Inc. • 04/11/2024 12:30:00 PM
- Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen • GlobeNewswire Inc. • 04/09/2024 03:59:00 PM
- Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 04/01/2024 08:00:00 PM
- Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient • GlobeNewswire Inc. • 03/19/2024 12:30:00 PM
- Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements • GlobeNewswire Inc. • 03/18/2024 12:30:00 PM
- Atossa Therapeutics Appoints Breast Cancer Specialist Tessa Cigler, M.D., M.P.H. to its Board of Directors • GlobeNewswire Inc. • 03/12/2024 12:30:00 PM
- Atossa Therapeutics Announces First Patient Dosing of (Z)-Endoxifen in the Ongoing RECAST DCIS Study • GlobeNewswire Inc. • 02/22/2024 01:30:00 PM
- Atossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical Trial • GlobeNewswire Inc. • 02/07/2024 01:30:00 PM
- Atossa Therapeutics Issues Letter to Shareholders • GlobeNewswire Inc. • 01/09/2024 01:30:00 PM
- Atossa Therapeutics Announces the Appointment of Arezoo Mirad, M.D., as Senior Medical Director • GlobeNewswire Inc. • 12/04/2023 01:30:00 PM
- Atossa Therapeutics Announces Full Enrollment of Phase 2 Karisma-Endoxifen Clinical Trial • GlobeNewswire Inc. • 11/20/2023 01:30:00 PM
- Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 11/15/2023 10:03:55 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 11/15/2023 09:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/15/2023 09:05:28 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2023 02:10:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 02:00:13 PM
- Atossa Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 11/13/2023 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 02:00:40 PM
- Atossa Therapeutics Appoints Financial Executive Jonathan Finn to its Board of Directors • GlobeNewswire Inc. • 11/09/2023 02:00:00 PM
- Quantum Leap Healthcare Collaborative Initiates Landmark Phase 2 RECAST DCIS Platform Trial to Evaluate Alternative DCIS Treatments with Atossa Therapeutics, Havah Therapeutics, and the Menarini Group • PR Newswire (US) • 10/30/2023 05:00:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 10/16/2023 08:00:20 PM
- Fast-food consumption by adolescent girls may sow the seeds of breast cancer decades later • PR Newswire (US) • 10/11/2023 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/06/2023 08:00:30 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM